Ergotamine tartrate / caffeine (Cafergot Tablet) and Imatinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Imatinib can inhibit CYP3A metabolism of a medicine with a narrow therapeutic range.
Clinical significance and safety
Cafergot Tablet contains a CYP3A substrate specifically covered by the GLEEVEC label’s narrow-therapeutic-range warning. Imatinib may increase exposure to the interacting medicine and its toxicity. Specialist assessment and drug-specific monitoring or an alternative plan are needed.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.